We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.
ARTICLE · 01 AUGUST 2013
IP Update, Vol. 16, No. 7, July 2013
McDermott Will & Emery
Resolving a split among the U.S. Courts of Appeals, the U.S. Supreme Court ruled that patent infringement settlement agreements between branded and generic drug manufacturers containing "reverse payment" provisions "can sometimes violate the antitrust laws".
United StatesIntellectual Property







